From bench to clinic with apoptosis-based therapeutic agents

A retrospective look at the basis of human disease pathogenesis almost always reveals an apoptotic component that either contributes to disease progression or accounts for it. What makes this field particularly exciting is the breadth of therapeutic opportunities that are on offer. The pace of apoptosis research has raised expectations that therapeutics will follow soon. But many of the organizations that are best placed to take advantage of these discoveries consider the ability to modulate the life or death of a cell for the purpose of disease treatment as perhaps being 'too good to be true'. Nevertheless, practical therapeutics that modulate apoptosis will no doubt appear in the clinic or on the shelf in the next few years.

[1]  H. Pehamberger,et al.  bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice , 1998, Nature Medicine.

[2]  M. Hayden,et al.  Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract , 1996, Nature Genetics.

[3]  Marcel Leist,et al.  Caspase inhibition reduces apoptosis and increases survival of nigral transplants , 1999, Nature Medicine.

[4]  D. Cunningham,et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  P. Hersey,et al.  Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells1 , 2000, The Journal of Immunology.

[7]  D. Lawrence,et al.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.

[8]  Patrick R. Griffin,et al.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis , 1995, Nature.

[9]  S. Korsmeyer,et al.  Prevention of lymphocyte cell death in sepsis improves survival in mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Junying Yuan,et al.  Human ICE/CED-3 Protease Nomenclature , 1996, Cell.

[11]  A. Yakovlev,et al.  Activation of CPP32-Like Caspases Contributes to Neuronal Apoptosis and Neurological Dysfunction after Traumatic Brain Injury , 1997, The Journal of Neuroscience.

[12]  N F LaRusso,et al.  Cholangiocarcinomas express fas ligand and disable the fas receptor , 1999, Hepatology.

[13]  T. Griffith,et al.  TRAIL: a molecule with multiple receptors and control mechanisms. , 1998, Current opinion in immunology.

[14]  Keisuke Kuida,et al.  Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice , 1996, Nature.

[15]  Matthias Mann,et al.  FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex , 1996, Cell.

[16]  J. Wyatt,et al.  Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides , 1999, Nature Biotechnology.

[17]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[18]  David Wallach,et al.  Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor–Induced Cell Death , 1996, Cell.

[19]  P. Vandenabeele,et al.  Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. , 1999, The Journal of clinical investigation.

[20]  John C Reed,et al.  Bcl-2 family proteins , 1998, Oncogene.

[21]  J. Tschopp,et al.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors , 1997, Nature.

[22]  J. Blenis,et al.  Caspase-8 Is Required for Cell Death Induced by Expanded Polyglutamine Repeats , 1999, Neuron.

[23]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[24]  K. Gale,et al.  Intracerebral injection of caspase-3 inhibitor prevents neuronal apoptosis after kainic acid-evoked status epilepticus. , 2000, Brain research. Molecular brain research.

[25]  J. Tschopp,et al.  Apoptosis induced by death receptors. , 2000, Pharmaceutica acta Helvetiae.

[26]  N. Thornberry,et al.  Inhibition of Human Caspases by Peptide-based and Macromolecular Inhibitors* , 1998, The Journal of Biological Chemistry.

[27]  P. Stieg,et al.  Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. , 2000, Science.

[28]  M. Ultsch,et al.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.

[29]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[30]  J. Adams,et al.  Potent and Selective Nonpeptide Inhibitors of Caspases 3 and 7 Inhibit Apoptosis and Maintain Cell Functionality* , 2000, The Journal of Biological Chemistry.

[31]  K. O. Elliston,et al.  A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes , 1992, Nature.

[32]  P. Auberger,et al.  A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  M. Ultsch,et al.  A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. , 2000, Biochemistry.

[34]  S H Kaufmann,et al.  Mammalian caspases: structure, activation, substrates, and functions during apoptosis. , 1999, Annual review of biochemistry.

[35]  N. Thornberry,et al.  A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B , 1997, The Journal of Biological Chemistry.

[36]  Natalie A. Lissy,et al.  Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein , 1999, Nature Medicine.

[37]  G. Robertson,et al.  Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. , 1999, Cell.

[38]  S. Cory Regulation of lymphocyte survival by the bcl-2 gene family. , 1995, Annual review of immunology.

[39]  J. Cleveland,et al.  Neuroprotection by a caspase inhibitor in acute bacterial meningitis , 1999, Nature Medicine.

[40]  J. Tschopp,et al.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.

[41]  G. Baxter,et al.  Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury , 2000, British journal of pharmacology.

[42]  M. Hayden,et al.  Cell death attenuation by `Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex , 1998, Cell Death and Differentiation.

[43]  J. Blenis,et al.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.

[44]  C. Nathan,et al.  Molecular Medicine © 1999 The Picower Institute Press Original Articles Peptidomimetic Fluoromethylketone Rescues Mice from Lethal Endotoxic Shock , 1999 .

[45]  H. Pehamberger,et al.  Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. , 2000, The Journal of investigative dermatology.

[46]  Shai Shaham,et al.  The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme , 1993, Cell.

[47]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[48]  M. Moskowitz,et al.  Attenuation of Delayed Neuronal Death after Mild Focal Ischemia in Mice by Inhibition of the Caspase Family , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[49]  John Calvin Reed Splicing and dicing apoptosis genes , 1999, Nature Biotechnology.

[50]  J. Cronenwett,et al.  A specific inhibitor of apoptosis decreases tissue injury after intestinal ischemia-reperfusion in mice. , 1999, Journal of vascular surgery.

[51]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[53]  H. Horvitz,et al.  Mechanisms and functions of cell death. , 1991, Annual review of cell biology.

[54]  C. March,et al.  Molecular cloning of the interleukin-1 beta converting enzyme. , 1992, Science.

[55]  W. El-Deiry,et al.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.

[56]  S. Nagata,et al.  Steering anti-cancer drugs away from the TRAIL , 2000, Nature Medicine.

[57]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[58]  J. Sheridan,et al.  Control of apoptosis signaling by Apo2 ligand. , 1999, Recent progress in hormone research.

[59]  David Smith,et al.  Involvement of Caspases in Proteolytic Cleavage of Alzheimer’s Amyloid-β Precursor Protein and Amyloidogenic Aβ Peptide Formation , 1999, Cell.

[60]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[61]  F. Natt,et al.  A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  D. Nicholson,et al.  Caspase structure, proteolytic substrates, and function during apoptotic cell death , 1999, Cell Death and Differentiation.